1.15
-2.54%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cibus
From its filings with the US Securities and Exchange Commission
Cibus is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CBUS. The SEC classifies its business as agricultural chemicals. In the fiscal year to 31 December 2025, it reported revenue of $3.6m and a net loss of $127.1m. At that date it held total assets of $305.0m and shareholders' equity of $21.8m.
Cibus’ business operates within the global seed market, where management estimates that aggregate trait value across both genetically modified organism (GMO) and non-GMO seeds globally represents approximately $12.0 billion.
Cibus’ primary business is focused on the development of plant traits for some of the world’s major agricultural crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. These plant traits can be licensed to seed companies for inclusion in their seed products for a royalty. This is not a new business model as many companies have developed traits that have been added to seed products and have garnered significant royalties for their developers over many years. Importantly, farmers are well acquainted with the value of these seeds with traits. Cibus’ initial focus is on productivity traits, which can be associated with improving crop yields in the face of challenges such as weeds, pests, and diseases, can address environmental challenges with an overall reduction in the use of chemicals like fungicides, insecticides, or fertilizers, or can make crops more adaptable to environmental factors such as heat and drought in the face of climate change. In the near term, Cibus’ priority pipeline program centers on Rice herbicide tolerance (HT) traits.
Quoted from its 10-K, filed 17 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 Jul 2017
- Employees
- 118
- Website
- calyxt.com ↗
- Head office
- 6455 NANCY RIDGE DRIVE, SAN DIEGO, CA, 92121
- Incorporated in
- DE
- Classification
- Agricultural Chemicals
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Rory RiggsChairman of the Board, Co-Founder, since 2023$500,011
- Dr. Peter BeethamPresident, Interim Chief Executive Officer, Co-Founder, Chief Operating Officer, Director, since 2023$500,011
- Dr. Greg GocalCo-Founder, Executive Vice President, Chief Scientific Officer$266,012
- Mr. Cornelis BroosChief Financial Officer$551,494
- Ms. Noel SauerSenior Vice President - Research
- Mr. Jason StokesChief Legal Officer, General Counsel and Corporate Secretary
- Mr. Mark FinnLead Independent Director$252,435
- Ms. Kimberly BoxDirector
- Mr. Craig WichnerDirector
- Mr. Jean-Pierre LehmannIndependent Director$202,435
- Mr. August MorettiIndependent Director$54,690
- Dr. Gerhard PranteIndependent Director$239,465
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 24
- Environment
- 24
- Social
- 26
- Governance
- 22
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Cibus Inc. has a patented RTDS technology platform with the Trait Machine for efficient trait development.
- Cibus focuses on gene-edited traits indistinguishable from traditional breeding methods.
- Cibus employs 236 full-time employees in San Diego, California, supporting its biotechnology research.
Weaknesses
- Cibus Inc. has only 118 employees as reported in the facts, not 236.
- Cibus is a small company with a limited workforce in the biotechnology sector.
- Cibus has a small market presence with no mention of significant partnerships or revenue.
Opportunities
- Cibus can expand its gene-edited trait development for climate change sustainability challenges.
- Cibus can leverage its RTDS technology to develop new productivity traits for seed companies.
- Cibus can target the growing demand for sustainable ingredients in the health care sector.
Threats
- Cibus faces competition from other biotechnology firms in the health care sector.
- Cibus must navigate regulatory challenges for gene-edited traits in the United States.
- Cibus has limited financial resources as a small company with no significant revenue.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.